ArticleDrug design, development and therapy2022
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice.
Martina Ranzenigo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.